Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Worlanyo Sosu Sedzorme"'
Autor:
Matthew B. Bloom, J.A. Marascio, Adam P. Dicker, Edouard J. Trabulsi, Bashar Dabbas, John L. Gore, Anne Calvaresi, Daniel E. Spratt, Whitney H. Beeler, Mark D. Hurwitz, Daniel W. Lin, W. Kevin Kelly, Elai Davicioni, Worlanyo Sosu Sedzorme, Tiffany Le, Robert B. Den, James L. Godwin, Mark Mann, Leonard G. Gomella, Peter A. McCue, Karen E. Knudsen, Costas D. Lallas, Jingbin Zhang, J Ryan Mark
Publikováno v:
Prostate Cancer and Prostatic Diseases
Background Genomic classifiers (GC) have been shown to improve risk stratification post prostatectomy. However, their clinical benefit has not been prospectively demonstrated. We sought to determine the impact of GC testing on postoperative managemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c029416c8cd997a56505dc048312037
https://pubmed.ncbi.nlm.nih.gov/31719663
https://pubmed.ncbi.nlm.nih.gov/31719663
Autor:
Paul L. Nguyen, Marguerite du Plessis, Tiffany Le, Ashley E. Ross, Kasra Yousefi, Roanna Padre, Worlanyo Sosu-Sedzorme, Robert B. Den, Darlene L.Y. Dai, Elai Davicioni, John L. Gore
Publikováno v:
Journal of Clinical Oncology. 36:72-72
72 Background: Prostate cancer patients and providers confront uncertainty as they consider adjuvant or salvage radiation therapy (ART, SRT) after radical prostatectomy (RP). We prospectively evaluated the impact of the Decipher RP test, which predic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9eb78b23b219452bb03f56ea1759621
https://doi.org/10.1200/jco.2018.36.6_suppl.72
https://doi.org/10.1200/jco.2018.36.6_suppl.72
Publikováno v:
Development (Cambridge, England). 134(11)
Drosophila Nemo is the founding member of the Nemo-like kinase(Nlk) family of serine/threonine protein kinases that are involved in several Wnt signal transduction pathways. Here we report a novel function for Nemo in the inhibition of bone morphogen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6b9f5fa5d95999d743131f4a287cc8a
https://pubmed.ncbi.nlm.nih.gov/17507407
https://pubmed.ncbi.nlm.nih.gov/17507407
Autor:
Christine Buerki, Benedikt Zimmermann, Ismael A. Vergara, Timothy J. Triche, Worlanyo Sosu-Sedzorme, Anamaria Crisan, Zaid Haddad, Nicholas Erho, Sebastian Harko, Elai Davicioni, Thomas Sierocinski, Mercedeh Ghadessi
Publikováno v:
Journal of Clinical Oncology. 30:37-37
37 Background: More than 90% of patients diagnosed with organ-confined prostate cancer (PCa) choose upfront definitive treatment (e.g., radical surgery) even though many are excellent candidates for delayed therapy (i.e., active surveillance [AS]). T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a82551d0d91b3fbbefcce365c7a2c6f7
https://doi.org/10.1200/jco.2012.30.30_suppl.37
https://doi.org/10.1200/jco.2012.30.30_suppl.37
Autor:
Worlanyo Sosu-Sedzorme, Christine Buerki, Anamaria Crisan, Peter C. Black, Zaid Haddad, Mercedeh Ghadessi, Ismael A. Vergara, Sebastian Harko, Nicholas Erho, Benedikt Zimmermann, Thomas Sierocinski, Darby J. S. Thompson, Robert B. Jenkins, Elai Davicioni
Publikováno v:
Journal of Clinical Oncology. 30:90-90
90 Background: Biochemical recurrence (BCR) may be an indicator of metastatic prostate cancer; however, it isn't specific enough to differentiate patients who will experience rapid onset of metastases from those who do not. Such lack of specificity l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8f7e23d02771099320adf0ac334a11c
https://doi.org/10.1200/jco.2012.30.30_suppl.90
https://doi.org/10.1200/jco.2012.30.30_suppl.90
Autor:
Thomas Sierocinski, Zaid Haddad, Sebastian Harko, Timothy J. Triche, Benedikt Zimmermann, Nicholas Erho, Elai Davicioni, Ismael A. Vergara, Christine Buerki, Mercedeh Ghadessi, Worlanyo Sosu-Sedzorme, Anamaria Crisan, Robert B. Jenkins
Publikováno v:
Journal of Clinical Oncology. 30:40-40
40 Background: Gleason score (GS) is the most widely used grading system of cell differentiation in prostate cancer and one of the best pathological predictors of disease progression. Patients with high GS (> 7) are the most likely to experience meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::918997572c10a01f8b174f9a08808ad5
https://doi.org/10.1200/jco.2012.30.30_suppl.40
https://doi.org/10.1200/jco.2012.30.30_suppl.40